Physcion increases the sensitivity of hepatocellular carcinoma to sorafenib through miRNA-370/PIM1 axis-regulated glycolysis

Figure 4 Physcion regulates hepatocellular carcinoma cell glycolysis via targeting PIM1. The sorafenib-resistant Huh7-SR and HepG2-SR cells were treated with physcion and/or sorafenib. A and B: RNA levels of LDHA, PGK1, PKM2, HK1, HK2, and GLUT1 in (A) Huh7-SR and (B) HepG2-SR cells were measured by quantitative real-time polymerase chain reaction (qPCR) assay; C: The protein levels of PIM1, LDHA, PGK1, PKM2, HK1, HK2, GLUT1, c-Myc, and phosphorylated c-Myc in cells were measured by qPCR assay; D and E: The RNA level of PIM1 in (D) Huh7-SR and (E) HepG2-SR cells were measured by qPCR assay. ^aP < 0.01, ^bP < 0.001 versus control (Cont) group; ^cP < 0.05, ^dP < 0.01, ^eP < 0.001 versus Cont + SF group. qPCR: Quantitative polymerase chain reaction; Cont: Control; SF: Sorafenib; phy: Physcion.